IngredientsD-Aspartic acid (D-Asp; also written as D-aspartate in its ionised form) is the D-enantiomer of the non-essential amino acid aspartic acid. It is one of the enantiomers of the amino acid known as aspartate, where the common dietary enantiomer is L-aspartate. "Aspartic acid" and "aspartate" are closely related structures — aspartate being the conjugate base of aspartic acid, with interconversion occurring depending on the pH of the solution. The "D" and "L" designations refer to the direction in which the molecule bends polarised light, and for all practical and metabolic purposes the two stereoisomers behave as distinct bioactive molecules.
The molecular formula is C₄H₇NO₄ (PubChem CID: 83887), with a molecular weight of 133.10 g/mol. The IUPAC name is (R)-2-aminosuccinic acid. In commerce and research, the compound is often encountered as its sodium salt (sodium D-aspartate), its calcium chelate, or occasionally its free acid form. Dietary supplements occur as D-aspartic acid or D-aspartate (the salt form) commonly sold as tablets, capsules, or powders. Some preparations contain metal (calcium or zinc) chelates, promoted as improving the body's absorption of D-Asp. The main biosynthetic route to D-Asp in vivo is racemisation of L-Asp. In the pituitary and testes specifically, D-Asp is synthesised by a D-aspartate racemase that converts L-Asp into D-Asp.
D-aspartic acid is present in invertebrate and vertebrate neuroendocrine tissues, where it carries out important physiological functions and is implicated in nervous system development. D-Asp was first detected in the brain and optic lobes of the cephalopod mollusc Octopus vulgaris and was later found in the nervous and endocrine systems of various animal phyla. Subsequent research extended its confirmed presence to crustaceans, amphibians, reptiles, fish, chicken, rats, and humans. It has been identified in the nervous and endocrine systems of crustaceans, amphibians, reptiles, fish, chicken, rat, and humans.
D-aspartic acid is a physiological amino acid occurring principally in the pituitary gland and testes. It has been demonstrated that D-Asp, together with N-methyl-D-aspartate (NMDA), is present as a natural molecule in rat nervous system and endocrine glands, with both amino acids concentrated at nmol/g levels in the adenohypophysis, hypothalamus, brain, and testis.
D-Asp plays an important role in the neuroendocrine system and in the development of the nervous system. During the embryonic stage of birds and the early postnatal life of mammals, a transient high concentration of D-Asp takes place in the brain and in the retina. D-aspartic acid is abundant in the developing brain. Mammalian aspartate racemase (DR) converts L-aspartate to D-aspartate and colocalises with D-aspartate in the brain and neuroendocrine tissues.
D-Asp may be produced by the degradation of proteins derived from the diet or obtained from intestinal bacteria containing D-Asp. D-Asp is widely present in several plants, and some foods particularly rich in D-Asp might be useful in conditioning reproductive activity. D-aspartic acid is a normal constituent of all animal tissues at variable concentrations depending on the type of tissue, and is present in most common foods. The salified form (D-aspartate) is the physiological form present in animal and plant tissues.
Unlike botanical herbs or traditional plant medicines derived from ethnobotanical traditions, D-aspartic acid does not have a pre-modern history as an isolated or deliberately extracted compound. No formal traditional-medicine system — whether Ayurvedic, Traditional Chinese Medicine, Greek/Galenic, or other — is documented in the peer-reviewed scientific literature as employing D-Asp as a named therapeutic substance, because its existence as a discrete stereoisomeric molecule distinct from L-aspartate was only established with the development of modern analytical chemistry and high-performance liquid chromatography (HPLC) in the latter half of the 20th century.
D-aspartic acid is an endogenous amino acid occurring in several tissues and cells of both invertebrates and vertebrates. It was first detected in the brain and optic lobes of the cephalopod mollusc Octopus vulgaris, in work pioneered by Italian researcher Antimo D'Aniello and colleagues in 1977. Subsequent decades of research by this group and others built up the biochemical and neuroendocrine understanding that underpins the modern dietary supplement market for D-Asp.
The first documented therapeutic application of D-Asp as a supplementable compound for human reproductive health emerged from Italian academic research in the late 1990s and early 2000s. A patent describing the use of sodium D-aspartate for male infertility was filed and eventually commercialised as the product DADAVIT®, containing 3,120 mg of sodium D-Asp. A product containing D-Asp (DADAVIT), marketed in 2005, contains 3,120 mg of D-Asp per unit — the recommended daily dose — and during the period of commercialisation more than 10,000 units have been sold every year, with no reports of adverse effects related to the product notified. D-Asp subsequently entered the global sports supplement market, primarily positioned as a testosterone booster and male fertility aid.
In rats, D-ASP has been shown to activate the hypothalamo-pituitary-gonadal (HPG) axis by facilitating the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, luteinizing hormone (LH) from the pituitary gland, and testosterone from the testes. The molecular intermediary in this process has been elucidated: in males, D-ASP is converted to N-methyl-D-aspartic acid (NMDA) by D-aspartate methyltransferase (NMDA synthetase). In the hypothalamus, NMDA binds to its receptor — a subtype of the L-glutamate receptor — and potentiates glutamatergic neurotransmission, which results in the release of GnRH.
In the endocrine system, D-Asp is involved in the regulation of hormone synthesis and release. In the rat hypothalamus, it enhances gonadotropin-releasing hormone (GnRH) release and induces oxytocin and vasopressin mRNA synthesis.
In addition to its indirect action through the HPG axis, D-Asp acts directly within the testes at the level of steroidogenesis. D-Aspartic acid causes increases in testosterone synthesis via upregulation of the mRNA that produces a compound called StAR (Steroidogenic Acute Regulatory Protein), which regulates androgen synthesis in the Leydig cells. In rat testis Leydig cells, sodium D-aspartate increases the synthesis and release of testosterone, with cAMP implicated as a second messenger in this process. In the rat pituitary, sodium D-aspartate increases the release and synthesis of LH through the involvement of cGMP as a second messenger.
The L-Asp form does not induce any significant increase of serum LH or testosterone, indicating that only the D-stereoisomeric form of aspartate is active in hormone release. This stereospecificity is a defining characteristic of D-Asp pharmacology and is essential context when evaluating supplement labels, as some products contain racemic or predominantly L-form mixtures.
D-Asp is present in high concentrations in the synaptic vesicles of axon terminals; synthesis occurs in neurons by conversion of L-Asp to D-Asp via D-aspartate racemase; depolarisation of nerve endings evokes an immediate release of D-Asp in a Ca²⁺-dependent manner; specific receptors for D-Asp occur at the postsynaptic membrane; and stimulation of nerve endings with D-Asp triggers signal transduction by increasing the second messenger cAMP. Taken together, these data demonstrate that D-Asp fulfils all criteria necessary to be considered a novel endogenous neurotransmitter.
Depletion of aspartate racemase by retrovirus-mediated expression of short-hairpin RNA in newborn neurons of the adult hippocampus elicits profound defects in dendritic development and neuronal survival. Because D-aspartate is a potential endogenous ligand for NMDA receptors, the loss of which produces a phenotype resembling racemase depletion, D-aspartate may function as a modulator of adult neurogenesis.
D-Asp is a free D-amino acid found in the mammalian brain with a temporally dependent concentration based on postnatal expression of its metabolising enzyme D-aspartate oxidase (DDO). The concentration of D-Asp fluctuates over a lifetime, increasing during embryonic and perinatal periods and decreasing during adulthood. D-Asp is one of the NMDAR co-agonists; augmented D-Asp content is able to suppress long-term depression (LTD) in the striatum and to increase NMDAR-dependent hippocampal long-term potentiation (LTP) and spatial memory.
Endogenous D-Asp and NMDA have been confirmed in the neural complex and gonads of a protochordate, the ascidian Ciona intestinalis, and their involvement in hormonal activity has been demonstrated. In the cerebral ganglion, D-Asp is synthesised from L-Asp by an aspartate racemase, then transferred through the bloodstream into the neural gland where it gives rise to NMDA. NMDA in turn passes into the gonads where it induces the synthesis and release of GnRH, which in turn modulates the release and synthesis of testosterone and progesterone. All evidence implies that the D-Asp- and NMDA-mediated neuroendocrine roles remain largely unchanged along the entire chordate lineage, suggesting an evolutionary conservation of this signalling pathway from protochordates to mammals.
The seminal human clinical study was conducted by Topo et al. and published in Reproductive Biology and Endocrinology. A group of 23 men were given a daily dose of D-aspartate (DADAVIT®) for 12 days, while another group of 20 men were given a placebo. LH and testosterone accumulation were subsequently determined in serum, and D-aspartate accumulation in tissues was measured. The clinical trial in 23 healthy male volunteers consumed 3.12 g of sodium D-Asp for 12 consecutive days. Significant increases in LH and testosterone levels were found after 12 days: LH rose by 33% and testosterone by 42%. The recruited cohort were healthy sedentary male IVF patients aged 27–37 years, with low initial testosterone levels (~4.55 ng/mL). The study demonstrated that D-aspartic acid, occurring as a physiological compound in the mammalian pituitary and testis, has a role in the regulation of LH and testosterone release and synthesis. In humans and rats, sodium D-Asp treatment enhances the release of LH and testosterone.
Limitations: The study was small (n = 43 total), short in duration (12 days), and conducted in a population with below-normal baseline testosterone. These constraints significantly limit the generalisability of the findings.
Subsequent studies in resistance-trained men — a population with characteristically higher baseline testosterone — have failed to replicate the Topo et al. findings, and in some cases have found reductions.
Willoughby & Leutholtz (2013): Body composition, muscle strength, and serum hormone levels associated with the HPG axis were studied after 28 days of resistance training, with participants resistance training four times per week while orally ingesting either 3 g of placebo or 3 g of D-ASP. Resistance-trained men received 3 g/day of D-Asp or placebo for 28 days. The gonadal hormones were unaffected by D-Asp supplementation and were not associated with the observed increases in muscle strength and mass.
Melville, Siegler & Marshall (2015): D-Asp supplementation revealed no main effect for group in estradiol, sex-hormone-binding globulin, or albumin. Total testosterone was significantly reduced in the 6 g group (D6, P = 0.03). Analysis of free testosterone showed that D6 was significantly reduced compared to D0 (P = 0.005). The study demonstrated that a daily dose of six grams of D-aspartic acid decreased levels of total testosterone and free testosterone, without any concurrent change in other hormones measured.
Melville, Siegler & Marshall (2017, PLoS ONE RCT): A randomised, double-blind, placebo-controlled trial in healthy resistance-trained men aged 18–36 who had been performing regular resistance training for at least 3 days/week for the previous two years. Randomised participants were 22 men (D-aspartic acid n = 11; placebo n = 11). D-aspartic acid was given at 6 g/day versus an equal-weight, visually-matched placebo. All participants performed 12 weeks of supervised, periodised resistance training (4 days/week) focusing on all muscle groups. No change in basal total testosterone or free testosterone was observed after the intervention. DAA supplementation led to a 16% (95% CI −27% to −5%) reduction in estradiol (P < 0.01). The results indicated that DAA supplementation is ineffective at changing testosterone levels or positively affecting training outcomes. Reductions in estradiol and the blunting of peripheral excitability appeared unrelated to improvements from resistance training.
Research on D-aspartic acid has demonstrated increases in total testosterone levels in untrained men; however, research in resistance-trained men demonstrated no changes and reductions in testosterone levels. The difference in outcome between the earlier positive study and the null studies in trained men may in part be explained by training status and accompanying basal testosterone levels. The increase in testosterone observed in Topo et al. was likely due to the fact that testosterone levels were low enough for D-aspartic acid to have an effect. An elderly population with decreased testosterone levels may benefit from DAA supplementation combined with resistance training, as some research has demonstrated that DAA can improve testosterone levels in untrained men.
A 2017 systematic review retrieved 396 records and included 23 animal studies and 4 human studies. In vivo and in vitro animal studies revealed the effect of D-Asp to be dependent on species, sex, and organ. The review authors concluded that there is an urgent need for more well-designed human clinical trials with larger sample sizes and longer duration to investigate the putative effects of D-Asp on testosterone concentrations.
A study published in 2012 by D'Aniello and colleagues investigated the impact of sodium D-aspartate supplementation on sperm quality in sub-fertile patients. The study examined the impact of nutritional supplementation of sodium D-aspartate on the improvement of sperm quality in sub-fertile patients and the rate of pregnancies that occurred with their partners. Two groups were studied: 30 patients with oligo-asthenozoospermia and 30 patients with asthenozoospermia, each treated with a daily dose of sodium D-aspartate for 90 days. Supplementation of D-aspartate significantly increased both the concentration and the motility of spermatozoa. In oligo-asthenozoospermic patients the increase in sperm concentration was 2.0-fold (P < 0.001).
A more recent randomised double-blind placebo-controlled study examined D-Asp in combination with other micronutrients. A total of 75 infertile patients were recruited. Group A (24 patients) received 2,660 mg D-aspartic acid plus 200 mg of ubiquinol plus 10 mg zinc once daily for 3 months; Group B (24 patients) received placebo for 3 months. Patients in Group A showed significant improvement in progressive sperm motility after 3 months (10.63 ± 8.64 vs 15.21 ± 12.11, P = 0.047). A key limitation of this study is that D-Asp was not administered alone, making it impossible to attribute the observed effects to D-Asp specifically.
Oral D-Asp treatment improves the fertilising capability in mice regardless of age. A short D-Asp treatment of 2 weeks in young males elevates sperm parameters to the levels of untreated adult animals. In vivo, D-Asp treatment highly improves sperm quality but not sperm concentration. These animal findings are mechanistically supportive but cannot be directly extrapolated to human fertility outcomes without confirmatory controlled human trials.
Despite the theoretical link between testosterone and skeletal muscle anabolism, clinical studies have not demonstrated a body-composition benefit from D-Asp supplementation. Both the DAA and placebo groups exhibited increases in isometric strength of the plantar flexors by 17% (95% CI 7%–28%, P < 0.05) and similar increases in hypertrophy in the quadriceps and calf muscles. These comparable gains in both groups indicate that any effects on muscle strength and mass were attributable to the resistance training protocol rather than to D-Asp. The gonadal hormones were unaffected by D-Asp supplementation and were not associated with the observed increases in muscle strength and mass.
Evidence strength: Current evidence in resistance-trained individuals consistently shows no benefit of D-Asp on body composition or muscular performance. The overall evidence base in humans is limited to a very small number of studies with small sample sizes.
Administration of 40 mM sodium D-aspartate daily for 12–16 days enhanced neuronal function and memory in rats by increasing their ability to find a hidden platform in a Morris Maze test, decreasing the required time from 20–30 seconds to 5 ± 2 seconds. This dose caused no noticeable side effects after one month of treatment.
D-Asp has been proposed to promote early-phase long-term potentiation (LTP) in vitro and to enhance spatial memory in vivo. A study investigated the behavioural effects of chronic consumption of D-Asp on spatial learning in mice together with the expression of NMDA receptors. Results specified a time period (3–4 hours post-training) within which animals exposed to D-Asp showed a more stable memory during retrieval. The cognitive improvement was due to elimination of transient bouts of destabilisation and reconsolidation of memory, rather than to enhanced acquisition. Expression of GluN1 and GluN2A subunits was elevated in the hippocampus of D-Asp (but not D-serine) treated mice.
Oral drinking of D-Asp recovered LTP induction in the medial prefrontal cortex in a Fragile X syndrome mouse model. Chronic oral administration of D-Asp reversed behavioural deficits of cognition and locomotor coordination in these mice.
Evidence strength: All published evidence supporting D-Asp's cognitive and neurological effects derives from animal and preclinical models. No controlled human clinical trials on cognitive outcomes had been published as of the most recent literature searches. These findings are preliminary and cannot be extended to humans without appropriate clinical investigation.
D-Aspartate may have a role in female sexuality and reproduction, as it has been detected as a physiological component of follicular fluid, and its levels decline with age — a decline that correlates with the decline in reproductive potential. This observation derives from basic science/correlational data and has not been evaluated in controlled human clinical trials for any therapeutic indication in women.
Dietary supplements occur as D-aspartic acid or D-aspartate (salt of D-Asp) forms commonly sold as tablets, capsules, or powders. The following dosages have been reported in the primary clinical literature:
Examine.com cites the standard dose for D-aspartic acid as between 2,000–3,000 mg, taken daily. Different studies have used different supplementation protocols. Because D-Asp is not approved by the FDA for any condition and clinical studies are sparse, there is no official dose.
Side effects with D-aspartic acid supplementation are not usually reported in the literature. Although a few side effects like irritability, nervousness, headache, and tachycardia (increased heart rate) were reported in one study, these effects were also reported in the placebo group, and they are unlikely to be clinically relevant. More research is required to assess its safety in humans.
In patients with oligo-asthenozoospermia, a daily dose of 2,660 mg of D-Asp given for up to 3 months did not cause adverse effects or abnormal changes in laboratory parameters in treated patients.
A clinically relevant safety observation emerged from the higher-dose trials. A daily dose of six grams of D-aspartic acid decreased levels of both total testosterone and free testosterone in resistance-trained men, without any concurrent change in other hormones measured. This paradoxical suppression at the higher dose has not been fully mechanistically explained and warrants caution at supratherapeutic dosing. In the six-gram group, total testosterone was significantly reduced from baseline by approximately 12.5%, with a parallel decrease in free testosterone of approximately 15.3%.
In the 12-week RCT (Melville et al., 2017), DAA supplementation at 6 g/day led to a 16% reduction in estradiol (95% CI −27% to −5%, P < 0.01). The clinical significance of this reduction for bone density, cardiovascular health, or other estrogen-sensitive parameters over longer supplementation periods has not been evaluated in the existing literature.
D-Asp is catabolised in vivo by the enzyme D-aspartate oxidase (DDO). D-Asp is a free D-amino acid found in the mammalian brain with a temporally dependent concentration based on postnatal expression of its metabolising enzyme DDO. The concentration of D-Asp fluctuates over a lifetime, increasing during embryonic and perinatal periods and decreasing during adulthood. The existence of this endogenous catabolic pathway may limit the duration of any exogenous elevation, though long-term pharmacokinetic studies in humans are lacking.
D-aspartic acid is not explicitly prohibited according to the 2026 WADA List of Prohibited Substances.
Some supplements contain mixtures of L- and D-Asp; others contain only the L-Asp form. L-Asp may not have the same effects as D-Asp in the body. Purchasers of commercial preparations should verify through independent third-party analytical testing that the product contains the declared stereoisomeric form, as label accuracy in the supplement industry is not universally guaranteed.
The longest controlled human study in the literature extended to 12 weeks. No long-term safety data (beyond 3 months) from controlled clinical trials in humans is available in the published scientific literature as of the most recent systematic review of this compound.
Health conditions that D-aspartic acid may help support.
D-Aspartic Acid (D-Asp) is an endogenous amino acid in neuroendocrine tissues involved in the synthesis and release of LH and testosterone. A systematic review (Roshanzamir & Safavi, IJRB, 2017) found animal studies consistently demonstrate testosterone elevation, though human trials yield inconsistent results—some RCTs in infertile men and aging males show meaningful testosterone increases. It represents one of the most mechanistically characterized amino acid-based testosterone support compounds.
D-Aspartic Acid (DAA) has been marketed as an ergogenic aid based on its proposed ability to raise testosterone, which could theoretically enhance athletic performance. Multiple randomized controlled trials in resistance-trained men found no significant improvements in strength, body composition, or performance biomarkers compared to placebo. A systematic review of five RCTs using doses of 3–12 g/day over 2–12 weeks confirmed these null findings.
NMDA receptors in the hypothalamic paraventricular nucleus play a documented role in mediating penile erection via nitric oxide signaling, and D-Asp is an endogenous NMDA receptor agonist. Animal research shows that excitatory amino acid levels, including D-Asp-related ligands, rise in the paraventricular nucleus during sexual activity and that NMDA receptor blockade impairs erectile responses. No human RCTs have directly tested DAA supplementation for erectile dysfunction.
D-Aspartic acid (D-Asp) is an endogenous amino acid found in high concentrations in the testis and pituitary that stimulates LH and testosterone release. A clinical study of 60 subfertile men found that 2.66 g/day sodium D-aspartate for 90 days significantly increased sperm concentration (2-fold in oligoasthenozoospermic patients) and motility, with 27% of partners becoming pregnant. A 2025 RCT confirmed significant improvements in progressive sperm motility vs. placebo.
D-Asp has been observed in animal and in vitro studies to stimulate growth hormone (GH) release from the pituitary gland. This is part of its broader neuroendocrine signaling role, acting upstream via hypothalamic GnRH stimulation and directly at the pituitary. Human clinical data specifically measuring GH responses to DAA supplementation are limited.
D-Aspartic Acid (D-Asp) is an endogenous amino acid found in neuroendocrine tissues that stimulates GnRH, LH, and testosterone release. A 2009 human RCT found 3.12 g/day for 12 days increased testosterone by ~42% in men; however, subsequent trials in athletes with normal testosterone showed no effect. Evidence is stronger for men with sub-optimal testosterone levels.
D-Asp acts as an endogenous NMDA receptor agonist in the brain, and elevated D-Asp levels are associated with enhanced hippocampal long-term potentiation (LTP) and improved spatial memory in animal models. A mouse study in Scientific Reports found that chronic D-Asp consumption selectively promoted intermediate-term spatial memory and upregulated hippocampal NMDA receptor subunits. Evidence is preclinical; human clinical trials on memory are absent.
D-Asp is an endogenous amino acid with a documented role in nervous system development and function. It occurs transiently at high concentrations in the embryonic and early postnatal brain, where it is implicated in neurogenesis and neural differentiation. It is found in synaptosomes and synaptic vesicles and fulfills several classical neurotransmitter criteria.
D-Asp functions as an endogenous NMDA receptor agonist and neuromodulator that influences multiple neurotransmitter systems, including glutamatergic, dopaminergic, and GABAergic signaling. It regulates the release of dopamine, GABA, and hormones such as GnRH and oxytocin within the hypothalamus. Evidence is primarily from animal and mechanistic studies.
D-Aspartic Acid (DAA) is an endogenous amino acid that acts on the HPG axis, stimulating release of LH and testosterone. An early RCT in untrained men showed significant testosterone increases, but subsequent trials in resistance-trained men showed no benefit or even decreases. Systematic reviews conclude evidence in humans is inconsistent, though animal data consistently shows testosterone-elevating effects.
Body systems that D-aspartic acid may help support.
Go back